文献速递细菌感染、耐药与抗菌药物

头孢吡肟/齐德巴坦对英国国家参考实验室耐药革兰阴性菌的活性

Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究用琼脂稀释法测定头孢吡肟/齐德巴坦对1632株肠杆菌目、745株铜绿假单胞菌和450株其他非发酵菌的MIC。结果显示8+8 mg/L可抑制多数产AmpC、ESBL、KPC、OXA-48样酶的肠杆菌目及90.5%产MBL菌株,对铜绿假单胞菌和非发酵菌也有良好活性。

要点

  • 头孢吡肟/齐德巴坦8+8 mg/L对多数耐药肠杆菌目和铜绿假单胞菌有活性。
  • 对产MBL肠杆菌目,90.5%(190/210)被8+8 mg/L抑制。
  • 产NDM合并OXA-48样酶及部分MBL耐药与肺炎克雷伯菌ST14相关。

核心结论

  • 头孢吡肟/齐德巴坦有望广泛克服肠杆菌目和非发酵菌的关键耐药,但需临床试验验证。

研究设计与样本

  • 英国国家参考实验室接收的连续问题革兰阴性菌,用BSAC琼脂稀释法测定MIC。
  • 共纳入1632株肠杆菌目、745株铜绿假单胞菌和450株其他非发酵菌。

主要发现

  • 对产AmpC、ESBL、K1、KPC、OXA-48样酶或膜通透性降低及未明确机制的耐药肠杆菌目,8+8 mg/L均敏感。
  • 头孢吡肟/齐德巴坦8+8 mg/L抑制190/210(90.5%)产MBL肠杆菌目,而头孢他啶/阿维巴坦等对照药物未显示同等活性。
  • 对103株产ESBL或MBL铜绿假单胞菌,97株(94.5%)被8+8 mg/L抑制,对照药物敏感率均低于15%。
  • 对产获得性OXA碳青霉烯酶的鲍曼不动杆菌,MIC集中在8+8至32+32 mg/L,产MBL菌株MIC更高。

关键数值与推荐

  • 头孢吡肟/齐德巴坦8+8 mg/L对多数耐药肠杆菌目和铜绿假单胞菌的抑制率见上述数值。
  • 对产MBL肠杆菌目中少数耐药及13/24产NDM合并OXA-48样酶菌株耐药与肺炎克雷伯菌ST14相关。
  • 铜绿假单胞菌中,高外排组85株仅11株MIC超过8+8 mg/L。

临床怎么用

  • 对碳青霉烯耐药肠杆菌目和铜绿假单胞菌感染,头孢吡肟/齐德巴坦可能覆盖多数产酶耐药株,包括部分产MBL株。
  • 对产NDM合并OXA-48样酶的肺炎克雷伯菌ST14及部分MBL株需警惕耐药。

局限性

  • 研究为体外MIC测定,临床疗效需待临床试验证实。
  • 部分MBL耐药机制及ST14相关耐药的具体遗传基础未在摘要中阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-action diazabicyclooctanes, e.g. zidebactam, combine β-lactamase inhibition, antibacterial activity, and 'enhancement' of PBP3-targeted β-lactams. OBJECTIVES: To examine the activity of cefepime/zidebactam against consecutive 'problem' Gram-negative bacteria referred to the UK national reference laboratory. METHODS: MICs were determined by BSAC agar dilution for 1632 Enterobacterales, 745 Pseudomonas aeruginosa and 450 other non-fermenters, categorized by carbapenemase detection and interpretive reading. RESULTS: Universal susceptibility to cefepime/zidebactam 8 + 8 mg/L was seen for otherwise multidrug-resistant Enterobacterales with AmpC, extended-spectrum, K1, KPC and OXA-48-like β-lactamases, or with impermeability and 'unassigned' mechanisms. Unlike ceftazidime/avibactam and all other comparators, cefepime/zidebactam 8 + 8 mg/L also inhibited most (190/210, 90.5%) Enterobacterales with MBLs. Resistance in the remaining minority of MBL producers, and in 13/24 with both NDM MBLs and OXA-48-like enzymes, was associated with Klebsiella pneumoniae ST14. For Pseudomonas aeruginosa, MICs of cefepime/zidebactam rose with efflux grade, but exceeded 8 + 8 mg/L for only 11/85 isolates even in the highly-raised efflux group. Among 103 P. aeruginosa with ESBLs or MBLs, 97 (94.5%) were inhibited by cefepime/zidebactam 8 + 8 mg/L whereas fewer than 15% were susceptible to any comparator. MICs for Acinetobacter baumannii with acquired OXA carbapenemases clustered around 8 + 8 to 32 + 32 mg/L, with higher values for MBL producers. A strong enhancer effect augmented activity against many isolates that were highly resistant to cefepime and zidebactam alone and which had mechanisms not inhibited by zidebactam. CONCLUSIONS: Assuming successful clinical trials, cefepime/zidebactam has scope to widely overcome critical resistances in both Enterobacterales and non-fermenters.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mushtaq S, Garello P, Vickers A, et al. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. J Antimicrob Chemother. 2021. PMID: 33760082. doi:10.1093/jac/dkab067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。